Regulation of IL-12 Expression and Activity by Oncogenes

描述（由申请人提供）：免疫能力是控制侵袭性肿瘤生长的最有效工具。白细胞介素-12 （IL-12）是维持这种能力所必需的分子。IL-12通过激活NK细胞、T细胞和巨噬细胞，对许多小鼠肿瘤和人类癌症具有强大的抗肿瘤活性，使肿瘤难以逃避免疫识别和攻击。编码IL-12、p40和p35两条异源链的基因位于不同的染色体上。p40和p35共同形成具有生物活性的IL-12。p40和p35基因的高度协调表达是有效免疫应答的关键。IL-12异二聚体的生物合成是由一个复杂的免疫调节活性网络控制的。在病因学上与肿瘤发生相关的肿瘤细胞及其产物可以深刻地影响与它们相互作用的免疫系统的反应，例如，IL-12的产生及其生物活性，可能作为逃避免疫监视和或阻止其对发展中的恶性肿瘤的攻击的手段。最近的证据表明，两种原癌基因c-Fos和c-Maf是与亮氨酸拉链转录因子相关的潜在候选基因。本研究的总体目标是了解c-Fos和c-Maf如何在细胞和分子水平上与免疫系统相互作用，以发挥其对IL-12产生的有效抑制作用及其免疫调节活性，IL-12是癌细胞逃避和延缓其生长和扩散的不良免疫反应的内在途径。我们将：(1)研究AP-1形式的c-Fos调控巨噬细胞和树突状细胞中IL-12生成的分子机制。(2)确定c- maf介导的IL-12基因表达抑制的分子基础，其在该活性中与AP- 1的相互作用，以及其对抗原提呈细胞基因表达和功能的整体影响。(3)在小鼠乳腺腺癌模型中验证AP-1抑制IL-12产生参与肿瘤易感性的假设。这些研究将为癌症诱导剂保护癌细胞的策略提供启示。它们还可能导致发现新的途径和确定新的靶点，从而使免疫干预在癌症治疗中受益。

DESCRIPTION (provided by applicant): Immune competence is the most effective tool with which to control the growth of invasive tumors. Interleukin-12 (IL-12) is a molecule essential for the maintenance of this competency. IL-12 has powerful anti-tumor activities against many murine tumors as well as human cancers through its ability to activate NK, T cells, and macrophages, making it very difficult for tumors to escape from immune recognition and attack. The genes encoding the two heterologous chains of IL-12, p40 and p35 are located on different chromosomes. Together, p40 and p35 form the biologically active IL-12. The highly coordinated expression of p40 and p35 genes is pivotal for effective immune responses. The biosynthesis of IL-12 heterodimer is controlled by a complex network of immune-modulating activities. Tumor cells and their products that are etiologically associated with tumorigenesis can profoundly influence the response of the immune system that they interact with, e.g., IL-12 production and its bioactivities, potentially as means of evading immune surveillance and or thwarting its attack on the developing malignancy. Recent evidence has implicated two proto-oncogenes, c-Fos and c-Maf that are related basic leucine zipper transcription factors, as potential candidates in this category. The overall aim of this proposal is to understand how c-Fos and c-Maf interact with the immune system at cellular and molecular levels to exert their potent inhibitory effects on IL-12 production and its immunoregulatory activities as an intrinsic way of cancer cells to escape and retard adverse immune response to their growth and spread. We will: (1) Investigate the molecular mechanism by which c-Fos in the form of AP-1 regulates the production of IL-12 in macrophages and dendritic cells. (2) Determine the molecular basis of c-Maf-mediated inhibition of IL-12 gene expression, its interaction with AP- 1 in this activity, and its global impact on gene expression and function of antigen-presenting cells. (3) Test the hypothesis that inhibition of IL-12 production by AP-1 is contributory to tumor susceptibility in a murine mammary adenocarcinoma model. These studies will shed light on the strategies of cancer-inducing agents for the protection of cancer cells. They may also lead to discovery of novel pathways and identification of new targets for the benefit of immune interventions in cancer therapy.